icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria áapril 22-26
Back grey_arrow_rt.gif
 
 
 
Steady-State Pharmacokinetics and Safety of Co-administration of Pan-Genotypic Direct Acting Protease Inhibitor ABT-493 with Pan-Genotypic NS5A Inhibitor ABT-530 in Healthy Adult Subjects
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Chih-Wei Lin, Wei Liu, Armen Asatryan, Andrew Campbell, Weihan Zhao, Haoyu Wang, Dilraj Sidhu, Jack Clifton II, Jens Kort and Sandeep Dutta AbbVie Inc., North Chicago, Illinois, United States
 
This may have flown under your radar, Abbvie's EASL press release said
http://www.natap.org/2015/EASL/EASL_01.htm:
 
AbbVie's ongoing HCV pipeline development program focuses on investigating a pan-genotypic, ribavirin (RBV)-free, once-daily treatment that may also allow for treatment durations of as little as eight weeks. Preliminary results from a Phase 2b study (n=79) of ABT-493 and ABT-530 in non-cirrhotic GT1 patients receiving the RBV-free recommended regimen for 12 weeks demonstrated a sustained virologic response rate at four weeks post treatment (SVR4) of 99 percent (n=78/79). These results, announced for the first time today, included both GT1a and GT1b, treatment-na´ve and pegylated-interferon and RBV prior null responders. Patients across both study arms were randomized to receive ABT-493 (200mg) and either 120mg or 40mg of ABT-530. To date, the most common (>5 percent) adverse reactions were fatigue, headache, nausea, diarrhea and anxiety. Data from these Phase 2b studies of ABT-493 and ABT-530 will not be presented at ILC 2015, and will be released at future medical congresses.
 
ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage......
http://www.natap.org/2014/CROI/croi_14.htm
 
A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance......
http://www.natap.org/2014/AASLD/AASLD_51.htm
 
ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance.....
http://www.natap.org/2014/CROI/croi_11.htm
 

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif